Open Data

ES EN

Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Source: tmcnet.com
Published on 2021-04-28

« Santhera Pharmaceuticals Holding AG : Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne ...  »